1,593
Views
10
CrossRef citations to date
0
Altmetric
Respiratory

Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

, , , , , & show all
Pages 936-944 | Received 07 Mar 2016, Accepted 04 May 2016, Published online: 25 May 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Alain Vergnenègre & Christos Chouaïd. (2018) Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC). Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 519-528.
Read now
Zheng-Yi Zhou, Alex Mutebi, Simeng Han, Arielle G. Bensimon, Marie Louise Ricculli, Jipan Xie, Anand Dalal & Ken Culver. (2018) Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. Journal of Medical Economics 21:6, pages 577-586.
Read now
J. J. Carlson, W. Canestaro, A. Ravelo & W. Wong. (2017) The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. Journal of Medical Economics 20:7, pages 671-677.
Read now

Articles from other publishers (7)

Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous & William W. L. Wong. (2023) A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). PharmacoEconomics 41:8, pages 945-980.
Crossref
Xudong Zhang, Pingping Fang, Guangquan Su, Shuangying Gui & Aizong Shen. (2022) Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China. Journal of Comparative Effectiveness Research 11:12, pages 871-878.
Crossref
Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie & Meaghan Gibbs. (2020) Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Ye Peng, Fang Ma, Chongqing Tan, Xiaomin Wan, Lidan Yi, Liubao Peng & Xiaohui Zeng. (2019) Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Advances in Therapy 36:11, pages 3047-3058.
Crossref
C. Chouaid & A. Vergnenègre. (2018) Les coûts du cancer du poumon. Revue des Maladies Respiratoires Actualités 10:3, pages 192-197.
Crossref
Hamzeh Albaba, Charles Lim & Natasha B. Leighl. (2017) Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. PharmacoEconomics 35:12, pages 1195-1209.
Crossref
Mengjia Qian, Bijun Zhu, Xiangdong Wang & Michael Liebman. (2017) Drug resistance in ALK-positiveNon-small cell lungcancer patients. Seminars in Cell & Developmental Biology 64, pages 150-157.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.